Biopharmaceutical companies can't talk business strategy with investors for long these days without addressing the issue of US drug pricing and healthcare reform. That was the case during Johnson & Johnson’s commercial overview presentation Sept. 13, where Vice Chairman Joaquin Duato assured investors the diversified pharma is well positioned to absorb changes, whatever shape they take.
J&J executives stressed that the company derives all of its growth from volume, not from price increases. Duato boasted of...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

